Docket No. JJM5033USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simon W. Bayliff et al.

For : DIAGNOSTIC TEST DEVICES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth

in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

	In ac	cordance with §1.129(a), this Information
Disclosure	Stat	ement is being filed in connection with \square the
first or []seco	nd After Final Submission, therefore:
		Statement in Accordance with §1.97(e)
		(attached); or
•		Please charge Deposit Account No. 10-
		0750/ / the fee of $$180.00$ as set forth
		in §1.17(p).
	In ac	cordance with §1.97(c), this Information
Disclosure	Stat	ement is being filed after the period set forth
in §1.97(b) abo	ve but before the mailing date of either a Fina
Action und	der §1	.113 or a Notice of Allowance under §1.311, or
an action	that	otherwise closes prosecution and that it is
accompanie	ed by	one of:
		Statement in Accordance with §1.97(e)
		(attached); or
		Please charge Deposit Account No. 10-
		0750/ / the fee of $$180.00$ as set forth
		in §1.17(p).
	In ac	cordance with §1.97(d), this Information
Disclosure	e Stat	ement is being filed after the mailing date of
either a F	Final	Action under §1.113 or a Notice of Allowance
under §1.	311 b	out before the payment of the Issue Fee.
Applicant ((s) he	reby petition(s) for consideration of this
Information	on Dis	closure Statement. Included are: Statement in
Accordance	e with	§1.97(e) as set forth below and the fee of
\$180.00 as	s set	forth in §1.17(p).

Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).
\square There are no listed references which are not in the English language.
The relevance of those listed references which are not in the English language is as follows:
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are

Please charge any deficiency or credit any overpayment to Deposit Account No. $10-0750/\mathrm{JJM}5033\mathrm{USPCT/BEL}$. This form is submitted in triplicate.

Respectfully submitted,

/Blossom E. Loo/

Blossom E. Loo Reg. No. 36,858 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1596
DATED: August 21, 2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	a valid OMB control number.
Application Number	
Filing Date	
First Named Inventor	Simon W. Bayliff
Group Art Unit	
Examiner Name	
Attorney Docket Number	JJM-5033USPCT

	Cite	U.S. Patent Doc	ument			
Examiner Initials			Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy
		5266266		Nason	11-30-1993	
		5770229		Tanihara et al.	06-23-1998	
		6248294	B1	Nason	06-19-2001	
		6524530	B1	Igarashi et al.	02-25-2003	
					1	
- · · ·						

FOREIGN PATENT DOCUMENTS

	TOREGOVATENT DOCUMENTO							
Examiner Initials			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T [©]		
•		wo	05/044110	Α	Kimberly-Clark Worldwide, Inc.	05-19-2005		X
				•				
			-	-				
			•					
· · · · · · · · · · · · · · · · · · ·								

Examiner	Date
Signature	Considered
Capitalance) United the second sec

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademank Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a unlif CMU.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a concentration minimization miless in dishibits a	TORG ONLO CONDON HUMBON.
Application Number	
Filing Date	
First Named Inventor	Simon W. Bayliff
Group Art Unit	
Examiner Name	
Attorney Docket Number	JJM5033USPCT

	1	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		VERONESE, F.M. et al. "Biconjugation in pharmaceutical chemistry", IL Farmaco 54, 497-516 (1999).	
		ULBRICH, K. et al. "Polymeric drugs based on conjugates of synthetic and natural macromolecules" Journal of controlled release 64, 63-79 (2000).	
	· · · · · · · · · · · · · · · · · · ·		

Examiner Date Signature Considered			
	Examiner	Date	
Opposition Control Con	Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.